Release date: 2016-12-28 1. Lilly: Alzheimer's disease drug Solanezumab It is very difficult to find a cure for Alzheimer's disease. It takes a lot of money to develop a “killer†product, and Eli has put a lot of effort and cost into it. In November, Lilly's headquarters announced that its Alzheimer's disease drug Solanezumab failed in a phase III clinical trial, which is seen as a hope for treating Alzheimer's disease. This is the second failure of Solanezumab in the final clinical trial, the first failure occurred in 2012. This time, Eli Lilly chose to focus the indications for mild Alzheimer's disease and used the "delayed start" theory. However, clinical phase III data showed that the Solanezumab treatment group did not significantly slow cognitive decline in data performance compared with the placebo group. With the failure of Solanezumab, Lilly announced that it will lay off staff in the sales team in 2017 to solve Solanezumab's accounting problems. 2, Bristol-Myers Squibb: lung cancer drug Opdivo Bristol-Myers Squibb (BMS) issued a statement in August that failed Opdivo as a monotherapy for previously untreated non-small cell lung cancer. PD1 immunosuppressant Opdivo This clinical trial was conducted in a wider patient population, with PDL1 levels as low as 5% in some patients. After the clinical failure of Opdivo, BMS announced that it will reorganize the R&D unit. In late October, the situation got worse. According to Cory Renauer, an expert at The Motley Fool, clinical trials have shown that the majority of patients receiving standard chemotherapy survive 40% longer than those who use Opdivo, and there are no signs of worsening the condition. The failure of the Opdivo clinical trial led to a 16% drop in BMS shares. 3, Bai Jian: multiple sclerosis medicine Opicinumab (lingo-1 antibody) Baijian's Opicinumab is a clinically researched, fully human-derived monoclonal antibody that effectively repairs nerve damage caused by multiple sclerosis. The gradual dissection of myelin leads to nerve damage in patients with multiple sclerosis. Lingo-1 is an important target for Baijian research for more than ten years. It is a membrane protein that can inhibit myelination. In June, the failure of the Phaseinumab Phase II clinical trial caused Baijian's share price to plummet and lost up to $8 billion in market value in one day. The drug did not meet the secondary endpoint at the primary endpoint of the clinical trial. 4. Celldex Therapeutics: Anti-brain cancer vaccine Rintega Celldex's anticancer vaccine Rintega announced the failure of Phase III clinical trials in March, which caused Celldex's share price to fall 80% this year. The company finally terminated Rintega's research. The vaccine is used to treat malignant gliomas and has received FDA “breakthrough therapy†certification. In spite of the significant losses, Celldex has other products with promising future prospects. Celldex's candidate glembatumumab vedotin, a protein substance that targets the tumor surface transmembrane glycoprotein non-metastatic melanoma protein B (gpNMB), is used to treat triple-negative breast cancer. 5, Juno Therapeutics: leukemia drug JCAR015 In November, Juno announced that its CAR-T immunotherapy, JCAR015, in Phase II clinical trials again resulted in the death of two patients, the fourth and fifth deaths associated with this trial. In July, Juno announced three deaths in the drug's clinical trial, which made the company once in trouble. According to Biospace's previous report, the first death patient took the B cell chronic lymphocytic leukemia drug fludarabine in addition to JCAR015, and the other two patients took chemotherapy drugs according to the treatment plan. All three patients died of cerebral edema. . The trial allowed a restart, but modifications were made and only patients who received cyclophosphamide care during the pretreatment period were allowed. In July, the litigation group filed an appeal against Juno, denying Juno a violation of federal security laws. The lawsuit was accepted in July, and the litigation group proposed that Juno CEO Hans Bishop and Juno had one patient died during the JCAR015 Phase II clinical trial, but they did not inform investors. 6, Clovis Oncology: lung cancer drug Rociletinib In the spring of 2016, Rociletinib, an anti-lung cancer drug developed by Clovis Cancer, a Colorado-based company, was not registered and approved, which brought a big blow to the company. Subsequently, Clovis announced that he decided to lay off 35% of the funds. In the end, Clovis received a full response from the FDA, canceling all ongoing Rociletinib clinical trial registrations. Although the Rociletinib clinical trial failed, Clovis could pin his hopes on his ovarian cancer drug Rucaparib. Rucaparib is a PARP inhibitor used to treat women with ovarian cancer who have previously received two platinum-based chemotherapy, germline or somatic BRAC gene mutations. Rucaparib received the FDA “Breakthrough Therapy†certification in April 2015, and in August 2016, the FDA granted Rucaparib a priority review. 7, Novavax: Respiratory Syncytial Virus (RSV F) vaccine In September, Novavax's share price plummeted 82% after Novavax released Phase III clinical trial data showing that its RSV F vaccine was not effective for elderly patients. In clinical phase III, the primary endpoint was to demonstrate the efficacy of the RSV F vaccine in the prevention of mild RSV-associated lower respiratory disease. The secondary endpoint was to demonstrate that the RSV F vaccine reduced the incidence of all respiratory diseases caused by RSV, but The clinical results of the RSV F vaccine were not up to standard. Source: E Drugs Facebook
Our products are exported to all over the world, facing Europe, America and Asia and other countries, there are a large number of hot products in stock at present, there are plant extracts, amino acids, Vitamins and other products, the price is preferential, quality assurance, is our very popular products in the market, waiting for your inquiry and purchase.
Plant Extracts,Amino Acids,Vitamin Products,Medical Excipients PYSON Co. ,Ltd. , https://www.pysonbio.com